JAMA : the journal of the American Medical Association
-
Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive. ⋯ Patent and regulatory reform is needed to ensure timely generic entry of GLP-1 receptor agonists to the market.